WST
West Pharmaceutical Services, Inc. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth +13.3% ·
share flow -2.2% ·
net new positions +11.8%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 175.10K | $64.20M | n/a | n/a |
| Q2 2026 | 160 | +3 | 50.04M | $17.95B | +8 | −6 |
| Q1 2026 | 161 | -2 | 49.75M | $12.46B | +4 | −7 |
| Q4 2025 | 162 | +3 | 53.70M | $14.74B | +5 | −1 |
| Q3 2025 | 21 | -1 | 26.99M | $7.08B | n/a | −2 |
| Q2 2025 | 20 | 0 | 24.84M | $5.43B | +1 | −1 |
| Q1 2025 | 17 | +2 | 8.37M | $1.87B | +2 | n/a |
| Q4 2024 | 15 | +2 | 8.55M | $2.80B | +2 | n/a |
| Q3 2024 | 12 | -1 | 4.43M | $1.33B | n/a | −1 |
| Q2 2024 | 13 | n/a | 5.33M | $1.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.20M | -1.3% | $717.21M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.85M | +4.2% | $413.70M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 903.77K | +1.9% | $202.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 522.83K | +588.0% | $117.05M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 5 | Gates Foundation Trust ✦ | 444.50K | New | $99.51M | 0.2% | New | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 304.40K | +38.6% | $68.15M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 280.73K | -58.2% | $62.85M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 211.11K | -13.0% | $47.26M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 9 | Marshall Wace ✦ | 166.10K | -26.9% | $37.19M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 10 | T. Rowe Price ✦ | 154.75K | -70.5% | $34.65M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 11 | Point72 Asset Management ✦ | 128.29K | -36.6% | $28.72M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 103.02K | -75.8% | $23.06M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | Arrowstreet Capital ✦ | 41.35K | New | $9.26M | 0.0% | New | 1 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 29.32K | +2.0% | $6.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Wellington Management ✦ | 13.49K | +102.7% | $3.02M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 16 | AQR Capital Management ✦ | 4.38K | -60.1% | $952,646 | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 17 | Gotham Asset Management ✦ | 2.09K | -3.3% | $467,909 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Gates Foundation Trust | $99.51M | 0.2% |
| Arrowstreet Capital | $9.26M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 749 holders, 70.07M shares, $16.37B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.52K sh · $921,260
Officer · 2.50K sh · $887,500
Officer · 2.50K sh · $862,500
Officer · 2.82K sh · $960,062
Officer · 2.82K sh · $960,403
Officer · 2.50K sh · $852,025
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology